2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.
Rachel E. Rau, MD, pediatric oncologist, Seattle Children’s Hospital, University of Washington, discusses results from the phase 3 Children’s Oncology Group Study AALL1731 (NCT03914625), which showed that adding blinatumomab (Blincyto) to chemotherapy improved 3-year disease-free survival rates in newly diagnosed, standard risk pediatric B-cell acute lymphoblastic leukemia. Rau and colleagues shared these results in a presentation at the 2024 ASH Annual Meeting.